Crescendo Bioscience Vectra DA Data to be Presented at American College of Rheumatology 2015 Annual Meeting

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc.

, today announced that new data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting being held Nov. 7-11, 2015 in San Francisco, Calif. Vectra DA is the first and only multi-biomarker blood test validated to measure disease activity in patients with RA and has been evaluated in multiple studies, resulting in 17 scientific publications. "Much work has been done over the past decade to develop and validate Vectra DA, and establish the test as an objective measure for assessing disease activity in patients with rheumatoid arthritis," said Elena Hitraya, M.D., Ph.D., chief medical officer, Crescendo Bioscience. "This year, our collaborators are presenting data on the role of Vectra DA in predicting response to second-line therapy. In addition, data will be presented examining Vectra DA's ability to predict which patients may be able to successfully taper or withdraw from treatment.  These data are important and deserve further exploration because they have the potential to help physicians tailor treatment plans for